Neonatal respiratory distress syndrome mesenchymal stem cell therapy - Human Life CORD Japan
Latest Information Update: 08 Mar 2022
At a glance
- Originator Human Life CORD Japan
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neonatal respiratory distress syndrome
Most Recent Events
- 24 Feb 2022 Neonatal respiratory distress syndrome mesenchymal stem cell therapy - Human Life CORD Japan is available for licensing as of 24 Feb 2022. https://www.humanlifecord.com/en/business.html
- 01 Dec 2021 Preclinical trials in Neonatal respiratory distress syndrome in Japan (Parenteral) (Human Life Cord Japan pipeline, December 2021)